NCT02081378 - A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | Biotech Hunter

Enrollment

326

Participants

Timeline

Start Date

April 24, 2014

Primary Completion Date

June 3, 2021

Study Completion Date

March 14, 2023

Conditions

Chronic Myelogenous LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic Leukemia

Interventions

DRUG

Asciminib (ABL001)

Asciminib was be administered orally in a dose escalation schedule.

DRUG

Nilotinib

Asciminib and Nilotinib was administered orally in CML patients

DRUG

Imatinib

Asciminib and imatinib was administered orally in CML patients

DRUG

Dasatinib

Asciminib and dasatinib was administered orally in CML patients

Trial Locations (18)

5000

Novartis Investigative Site, Adelaide

10065

Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering, New York

13353

Novartis Investigative Site, Berlin

28006

Novartis Investigative Site, Madrid

33076

Novartis Investigative Site, Bordeaux

48109

University of Michigan Comprehensive Cancer Center SC, Ann Arbor

60590

Novartis Investigative Site, Frankfurt

75475

Novartis Investigative Site, Paris

84112

Huntsman Cancer Institute SC, Salt Lake City

97239

Oregon Health Sciences University SC-6, Portland

169608

Novartis Investigative Site, Singapore

02215

Dana Farber Cancer Institute Hematology / Oncology, Boston

77030-4009

University of Texas/MD Anderson Cancer Center UT MD Anderson, Houston

07740

Novartis Investigative Site, Jena

00161

Novartis Investigative Site, Roma

650-0017

Novartis Investigative Site, Kobe

1081 HV

Novartis Investigative Site, Amsterdam

06591

Novartis Investigative Site, Seoul